{"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"BG000","title":"IV Busulfan"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.9","value":"59.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"25"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"}]}